Company Overview and News

20
Revisiting MLP Distribution Growth

2018-06-06 seekingalpha
It's a perennial favorite, with investors and industry insiders requesting it over and over again. We wanted to provide a simple number that could be referenced and compared. Something like the GDP growth rate, which on its face is a quick look at the economy, but in reality, is a simplified summary of a nuanced subject.
LINEQ ETP.PRC LGCYP LGCYO BBPPQ LNGG VNRR BBEP WPZ ETP VNR LGCY VNRAP VNRBP VNRCP BBEPQ EEP PAA BBEPP LINE

27
Lazard Ltd Reports First-Quarter 2018 Results

2018-04-26 businesswire
“Our clients and our shareholders are benefitting from investments we’ve made in the business, and we continue to pursue opportunities for growth.”
AGO.PRE CYH AGO.PRF BBPPQ AGO.PRB BBEP QCP ZODFY SRE.PRA SRE LAZ SU ZODFF AGO CYHHZ BBEPQ BBEPP ZC

111
E&P Bottom Of The Barrel Club #18-2: The Market Plays 'Whack-A-Mole'

2018-04-16 seekingalpha
After a 20% run-up in Club stocks in January, prices declined the rest of the quarter by -25%, with the Club finishing with an average return of -9%.
ECR CRC LGCYP LGCYO CRK REN EPE SCAZP BBEP MCEP MCF AREX RXNRP JNEEP XCOO SNZYP BBEPP SN BBPPQ EVEP JONE XCO REXX DNR LGCY WTI BBEPQ PQ

189
Energy Recap: Apple Comes Clean?

2018-04-13 seekingalpha
Every Friday, Seeking Alpha provides a roundup of insightful opinion and analysis articles in the energy sector.
NE BBPPQ NOBGF XOM N21 NOBGY AAPL BBEP BBEPQ GOOG BBEPP

5
Breitburn Energy Partners Successfully Completes Chapter 11 Reorganization: Emerges as Newly Formed Maverick Natural Resources, LLC, Controlled by Funds and Accounts Managed by EIG Global Energy Partners | Business Wire

2018-04-12 businesswire
LOS ANGELES--(BUSINESS WIRE)--Maverick Natural Resources, LLC (“Maverick”), announced today that it began operating on April 6, 2018, after it emerged from Chapter 11 as the successor to Breitburn Energy Partners LP (“Breitburn”). Maverick is majority-owned and controlled by funds and accounts managed by EIG Global Energy Partners (“EIG”).
BBPPQ BBEP BBEPQ BBEPP

7
Breitburn Energy Partners: Bankruptcy Proceedings Are Nearing The End

2018-03-21 seekingalpha
Second-lien bondholders will receive a strong recovery via ownership of Breitburn's legacy assets, while unsecured bondholders will receive a modest recovery.
LINEQ BBPPQ LNGG BBEP BBEPQ BBEPP LINE

6
Breitburn Reaches Bankruptcy Exit Deal With Holdout Creditors

2018-03-12 rigzone
March 12 (Reuters) - Breitburn Energy Partners LP has reached an agreement with holdout creditors over its $3 billion bankruptcy exit plan and hopes to win court confirmation as soon as this month for a reorganization under new ownership, a lawyer said on Monday.
BBPPQ BBEP BBEPQ BBEPP

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...